Tech Company Financing Transactions
Xeltis Funding Round
Horizon 3, DaVita Venture Group and EQT Life Sciences joined a $23.3 million funding round for Xeltis. This venture round closed on 7/28/2026.
Transaction Overview
Company Name
Announced On
7/28/2026
Transaction Type
Venture Equity
Amount
$23,300,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to finalize the ongoing US pivotal trial of aXess, prepare for FDA submission and US Go-To-Market, fund the European commercial rollout of aXess, upscale manufacturing capabilities, and advance its XABG and XPAD clinical programs.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
De Lismortel 31
Eindhoven, 5612AR
The Netherlands
Eindhoven, 5612AR
The Netherlands
Phone
Website
Email Address
Overview
Xeltis is a clinical-stage medical device company with the most advanced polymer-based restorative devices for cardiovascular treatment. Xeltis' devices naturally evolve into living blood vessels or heart valves, when colonized by patient's own tissue.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Eliane Schutte
Chief Financial Officer
Alexander Goemans
Chief Technical Officer
Martijn Cox
Vice President
Paulo Neves
Browse more venture capital transactions:
Prev: 7/28/2026: Greyparrot venture capital transaction
Next: 7/28/2026: Claros Technologies venture capital transaction
Share this article
News on VC Transactions
We do our best to report on all VC transactions involving tech companies. All VC database entries on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs